Tumor initiating cells escape tumor immunity via CCL8 from tumor-associated macrophages in mice

  • J Clin Invest. 2025 Jan 7:e180893. doi: 10.1172/JCI180893.
Shuang Chen  1 Chen-Song Huang  1 Kang Li  1 Maosheng Cheng  1 Caihua Zhang  1 Jianqi Xiong  1 Guoli Tian  2 Ruoxing Zhou  1 Rongsong Ling  1 Xiaochen Wang  1 Gan Xiong  3 Zhihui Zhang  1 Jieyi Ma  1 Yan Zhu  1 Bin Zhou  4 Liang Peng  5 Zhenwei Peng  1 Heping Li  3 Demeng Chen  1
Affiliations
  • 1. Department of Medical Oncology; Department of Pancreato-Biliary Surgery; De, Center for Translational Medicine, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.
  • 2. Hospital of Stomatology, Sun Yat-sen University, Guangzhou, China.
  • 3. Department of Medical Oncology, Sun Yat-sen Memorial Hospital, Sun Yat-sen University, Guangzhou, China.
  • 4. State Key Laboratory of Cell Biology, Shanghai Institute of Biochemistry an, Chinese Academy of Sciences; University of Chinese Academy of Sciences, Shanghai, China.
  • 5. Senior Department of Oncology, The Fifth Medical Center of PLA General Hospital, Beijing, China.
Abstract

Tumor-initiating cells (TICs) play a key role in Cancer progression and immune escape. However, how TICs evade immune elimination remains poorly characterized. Combining single-cell RNA Sequencing (scRNA-seq), dual-recombinase-based lineage tracing, and Other approaches, we identified a WNT-activated subpopulation of malignant cells that act as TICs in vivo. We found intensive reciprocal interactions between TICs and immune regulatory tumor-associated macrophages (Reg-TAMs) via GAS6-AXL/MERTK signaling pathways, which facilitated the immune escape of TICs. Our study employed chemical inhibitors and Axl/Mertk conditional double knockout mice to demonstrate that inhibiting the interaction between TIC-derived GAS6 and Axl/MERTK in Reg-TAMs reactivated anti-tumor immune responses. We identified CCL8 as a critical mediator of the GAS6/Axl/MERTK pathway, primarily by inhibiting regulatory T cell (Treg) infiltration into the tumor. Furthermore, the Axl/MERTK signaling blockade sensitized tumor cells to anti-PD-1 treatment. Thus, we elucidated a detailed mechanism by which TICs evade tumor immunity, providing insights into strategies to eradicate TICs that escape conventional immunotherapy.

Keywords
Cancer immunotherapy; Oncology.
Products